Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Short-term certoparin for persistent nonvalvular atrial fibrillation undergoing cardioversion
2004-002888-24Phase 3Completed
- Sponsor
- Novartis
- Start
- Sep 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of certoparin in Atrial fibrillation (AFib), sponsored by Novartis. Primary endpoint: Feasibility and safety of short-term fixed-dose certoparin. Started Sep 2005; status: completed.
02
Drugs
certoparin
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on 2004-002888-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-002888-24.